コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ctam is superior to both clavulanic acid and sulbactam.
2 ination of CMS, a carbapenem, and ampicillin-sulbactam.
3 as well as on the beta-lactamase inhibitor, sulbactam.
4 and 71 patients were treated with Ampicillin-Sulbactam.
5 s to ampicillin (100 versus 20%), ampicillin-sulbactam (100 versus 13%), vancomycin (100 versus 57%),
6 cultures [53.1%]; institution B: ampicillin-sulbactam, 9 [69.2%]; and institution C: penicillin, 32
7 -lactamase-inhibiting antibiotics ampicillin-sulbactam (A/S) and amoxicillin-clavulanic acid (A/C) fo
8 amoxicillin-clavulanate (AUG) and ampicillin-sulbactam (A/S) susceptibility testing by three differen
9 ure of the inhibitor preacylation complex of sulbactam, a clinical beta-lactamase inhibitor, bound in
10 azole, cefotetan, ampicillin, and ampicillin-sulbactam all promoted persistent high levels of stool V
12 bited increased susceptibility to ampicillin/sulbactam, an important difference compared to ampicilli
14 structures of the beta-lactamase inhibitors sulbactam and clavulanic acid bound to the deacylation-d
16 mately twice as much enamine intermediate as sulbactam and clavulanic acid, which correlates with its
18 ases in resistance were noted for ampicillin-sulbactam and clindamycin, while significant decreases i
22 phenotype, we investigated the activities of sulbactam and two novel penem beta-lactamase inhibitors
23 eta-lactamase and the inhibitors tazobactam, sulbactam, and clavulanic acid are followed in single cr
25 clinically relevant inhibitors, tazobactam, sulbactam, and clavulanic acid, and SHV beta-lactamase (
26 that for small ligands, such as tazobactam, sulbactam, and clavulanic acid, the positioning of the l
28 ve inhibitory activities of clavulanic acid, sulbactam, and tazobactam against clinically important b
29 0G variant that reacts with clavulanic acid, sulbactam, and tazobactam in solution, but lacks the cha
30 by the clinical inhibitors (clavulanic acid, sulbactam, and tazobactam), but the prevalence of inhibi
31 he clinically used inhibitors tazobactam and sulbactam are effective in the inhibition of activity of
32 tients receiving prophylaxis with ampicillin-sulbactam, aztreonam and vancomycin, or tigecycline (P =
33 with Enterobacter cloacae versus ampicillin-sulbactam, aztreonam, ticarcillin, and ticarcillin-clavu
34 dies of S130G SHV inhibited with tazobactam, sulbactam, clavulanic acid, and 2'-glutaroxy penem sulfo
35 aximal populations at 10, 22, and 29 min for sulbactam, clavulanic acid, and tazobactam, respectively
36 demonstrated 70 and 88 +/- 3 Da fragments of sulbactam covalently attached to the beta-lactamase.
38 y to obtaining the preacylation complex with sulbactam due to further decreased reactivity toward sub
39 t is demonstrated that with the exception of sulbactam, each compound forms observable trans-enamine
40 transferred ceftazidime resistance or showed sulbactam enhancement of oxyimino-beta-lactam susceptibi
41 One of the most promising combinations is sulbactam-ETX2514, whose potent antibacterial activity,
42 t species, with SHV-1, while clavulanate and sulbactam form a mixture of trans-enamine and two labile
43 running the reactions with the two forms of sulbactam in parallel, provides an element of control an
49 ith penicillin G, ampicillin, and ampicillin-sulbactam MICs and inhibition zones on penicillin (2-U)
50 am forms a larger population of enamine than sulbactam or clavulanic acid does and that tazobactam's
55 ss spectrometry analysis of SHV inhibited by sulbactam showed that SHV-1 beta-lactamase was unmodifie
60 It is proposed that for the unsubstituted sulbactam the conversion from imine to enamine, which in
62 s us to conclude that, for the unsubstituted sulbactam, the formation of the cross-linked intermediat
65 od susceptibilities but only with ampicillin-sulbactam, ticarcillin-clavulanate, and/or clindamycin.
66 acillin, piperacillin-tazobactam, ampicillin-sulbactam, ticarcillin-clavulanate, cefotaxime, cefoteta
67 a three-day treatment regimen of Ampicillin-Sulbactam to that of a three-day regimen of Ertapenem in
68 hibitors of class A beta-lactamases, such as sulbactam, undergo a complex series of chemical reaction
69 and DD were unacceptably high for ampicillin-sulbactam (VM error, 9.8%; minor [m] error, 16.1%), pipe
70 -S, -Q, and -L) variants revealed the Ki for sulbactam was significantly elevated for the R244 varian
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。